Drug Development
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
FEATURED STORIES
Together with robust data-driven modeling, rethinking regulation and data use could push forward a notoriously challenging field.
From opening new therapeutic mechanisms to repairing neuronal damage, investigational molecules from Ventyx Therapeutics, AC Immune, Gain Therapeutics and more could shape the future of Parkinson’s disease treatment.
As drug candidates discovered via AI move into later-stage clinical trials, the technology seems to be doing as promised: speeding drug development.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
Merck and Ridgeback Biotherapeutics’ antiviral drug molnupiravir, which showed great promise against COVID-19 in clinical trials, received its first authorization.
Both Moderna and Pfizer reported third-quarter financials this week, and it was instantly obvious that the COVID-19 vaccines are huge profit drivers for the companies.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Researchers with the University of Cambridge in the UK for the first time leveraged human data to quantify the speed of various processes in the brain that lead to Alzheimer’s disease.
While some may wonder about the commercial future of these late-to-the-market solutions, the developers themselves are taking a long view.
This week, the U.S. Food and Drug Administration accepted Investigational New Drug Applications for multiple companies, clearing the way for clinical development.
The annual Clinical Trials on Alzheimer’s Disease conference is scheduled for November 9-12, and Biogen plans to present data on its portfolio, including its controversial Aduhelm.
This first-of-its-kind collaboration will leverage the talent and innovation at companies such as Tessera Therapeutics to advance multiple candidates to human proof of concept.
CytoDyn announced two separate stories about its drug leronlimab today, one for nonalcoholic steatohepatitis and the other for metastatic triple-negative breast cancer.
The decision follows a 14-0 vote among members of an expert panel advising the agency.